Loading clinical trials...
Loading clinical trials...
A Phase I/II Study of Capecitabine (XELODA®, Roche) Plus Oxaliplatin (Eloxatin®, Sanofi) Plus ZD 1893 (IRESSA®) in the Treatment of Metastatic Colorectal Cancer
Conditions
Interventions
capecitabine
gefitinib
+1 more
Locations
1
United States
Roswell Park Cancer Institute
Buffalo, New York, United States
Start Date
January 1, 2004
Primary Completion Date
November 1, 2005
Last Updated
February 1, 2013
NCT06696768
NCT04704661
NCT05489211
NCT06625775
NCT04657068
NCT06445062
Lead Sponsor
Roswell Park Cancer Institute
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions